Abstracts

Skip to Late-Breaking Abstracts »

Poster Presentation Dates

All odd numbered posters will be presented on Friday, November 8, 2019, while even numbered posters will be presented on Saturday, November 9, 2019.

Posters will be on display from 7 a.m. - 8 p.m., with the presenting authors required to be at their posters during lunch (12:30 - 2 p.m. on Friday, Nov. 8, and 12:35 - 2:05 p.m. on Saturday, Nov. 9) and also during the poster reception (6:30 - 8p.m. on Friday, Nov. 8, and 7 - 8:30 p.m. on Saturday, Nov. 9).


Search word or phrase:

# Title Authors Category Keywords
O4 Preclinical CAR-T cell target safety, biodistribution, and tumor infiltration analysis using in situ hybridization technology Courtney M. Anderson, PhD; Helly Xiao Yan Pimentel; Helen Jarnagin; Hailing Zong; Courtney Todorov; Kenneth Ganley; Fay Eng; Kevin Friedman, PhD; Molly R. Perkins; Shannon Grande, PhD; Bingqing Zhang; Christopher Bunker; Xiao-Jun Ma; James R. Rottman; Courtney M. Anderson, PhD; Cellular Therapies CAR T cells; Cytokine; Gene expression; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment
O5 The road-map to Tumor-Infiltrating Lymphocyte (TIL) therapy: Understanding genetic alterations for improved patient treatment Caitlin Creasy, MS; Yuzhong J. Meng, PhD; Tatiana Karpinets, MS; Cara Haymaker, PhD; Marie Andrée Forget, PhD; Chip Stewart, PhD; Carlos Antonio Torres Cabala, MD; Shari A. Pilon-Thomas, PhD; Amod A. Sarnaik, MD; Levi A. Garraway, MD, PhD; Patrick Hwu, MD; Rodabe N. Amaria, MD; Rameen Beroukhim, M.D, PhD; Chantale Bernatchez; Cellular Therapies Adoptive immunotherapy; Clinical trial; Gene expression; Immune contexture; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
O6 Enhanced presence of a myeloid-like NK cell subpopulation is associated with MHC class I-deficient tumor escape Yimin Du, PhD; Curtis J. Perry, MD/PhD; William Damsky, MD, PhD; Katherine Hastings, PhD; Patricia Rodriguez-Morales; Dan Chen, PhD; Kacie Traina; Ivy Phung; Ting Zhou; Aaron M. Ring, MD, PhD; Katerina Politi, PhD; Susan M. Kaech, PhD; Cellular Therapies Immune suppression; Myeloid cells; NK/NK T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment
O7 P-BCMA-ALLO1 — a Nonviral, Allogeneic Anti-BCMA CAR-T Therapy with Potent Antitumor Function for the Treatment of Multiple Myeloma Maximilian Richter, PhD; Stacey Cranert, PhD; Yening Tan, MS; Min Tong, MS; Christine Domingo, BS; Elvira Argus, PhD; Samad A. Ibitokou, PhD; Jenessa B. Smith, PhD; Christopher E. Martin, PhD; Xinxin Wang, PhD; Burton E. Barnett, PhD; Eric M. Ostertag, MD, PhD; Julia Coronella, PhD; Devon J. Shedlock, PhD; Cellular Therapies Adoptive immunotherapy; CAR T cells
O8 The Thrombospondin-1/CD47 signaling axis serve as potential markers of immune checkpoint blockade response modulating immune cell bioenergetics in the tumor microenvironment. Elizabeth R. Stirling, MS; Adam Wilson; Mitra Kooshki; Lilya Yamaleyeva; Guanxu Jin; Wei Zhang; Lance D. Miller, MS, PhD; Pierre L. Triozzi, MD; David R. Soto-Pantoja, PhD; Cellular Therapies Biomarkers; Checkpoint blockade; Metabolism; Tumor microenvironment
O9 Enhancing affinity of CD22-directed CAR T cells increases activation signaling and in vivo response to CD22lo leukemia Zachary H. Walsh, BA; Mark Kohler, MD, PhD; Terry J. Fry, MD; Zachary H. Walsh, BA; Cellular Therapies Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; Pediatric tumors; T cell; Targeted therapy; Tumor evasion
O10 Licensing of CAR-T cell persistence and function by STING agonist in breast cancer Nuo Xu, PHD candidate; Jonathan S. Serody, MD; Nuo Xu, PHD candidate; Nicholas P. Restifo, MD; Douglas C. Palmer; Cellular Therapies Adoptive immunotherapy; CAR T cells; Solid tumors; T cell; Targeted therapy; Tumor microenvironment
P145 Expanding Iovance’s tumor infiltrating lymphocytes (TIL) from core biopsies for adoptive T cell therapy using a 22-day manufacturing process Michelle R. Abelson, PhD; Kenneth D'Arigo; Florangel Hilton; Maria Fardis, PhD, MBA; Cecile Chartier; Cecile Chartier Cellular Therapies Adoptive immunotherapy; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs)
P146 AUTO6NG: Next generation GD2-targeting CAR T-cell therapy with improved persistence and insensitivity to TGFb and checkpoint inhibition for relapsed/refractory neuroblastoma Daniela Achkova, PhD; Adrian Zarzoso; Yusuf Demir; Fernando J. Gallardo; Maria Stavrou; Marco Della Peruta; Saket Srivastava; Mathew Robson; Shimobi Onuoha; Simon Thomas; Shaun Cordoba; Martin Pule; Cellular Therapies Adoptive immunotherapy; CAR T cells; Checkpoint blockade; Cytokine; Solid tumors
P147 Effect of chemotherapy on cellular kinetics of NKG2D-based CAR T-cells in metastatic colorectal cancer patients. Erik Marcelo Alcantar Orozco; Eytan Breman, MSc; Marie-Sophie Dheur, PhD; Fabian Borghese, PhD; Emilie Cerf, PhD; Nathalie Braun; Caroline Lonez, PhD; Anne Flament; Frederic Lehmann, MD; Cellular Therapies Adoptive immunotherapy; CAR T cells; Chemotherapy; Clinical trial; Immune monitoring; Solid tumors; T cell
P148 High affinity NK cells expressing a PD-L1 chimeric antigen receptor demonstrate anti-tumor activity in head and neck cancer through multiple distinct mechanisms Yevtte Robbins; Jay Friedman, PhD; Sarah Greene; Kellsye Fabian, PhD; Michelle Padget; John Lee, MD; Patrick Soon-Shiong, MD; Kayvan Niazi; Lennie Sender; Laurent Boissel; Jeffrey Schlom, PhD; James W. Hodge, PhD, MBA; Clint T. Allen, MD; Cellular Therapies MDSC; NK/NK T cell; Tumor microenvironment
P149 Silencing PD-1 using self-delivering RNAi PH-762- to improve Iovance TIL effector function using Gen 2 manufacturing method Inbar Azoulay-Alfaguter, PhD; Michelle R. Abelson, PhD; Krit Ritthipichai, DVM, PhD; Kenneth D’Arigo; Florangel Hilton; Marcus Machin, BS; Dingxue Yan; James Cardia; Maria Fardis, PhD, MBA; Cecile Chartier; Cellular Therapies Adoptive immunotherapy; Gene expression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs)
P150 1st-in-human CAR T clinical trial for metastatic breast cancers Cynthia C. Bamdad, PhD; Andrew K. Stewart, PhD; Pengyu Huang, PhD; Benoit J. Smagghe, PhD; Scott T. Moe, PhD; Tyler E. Swanson; Thomas G. Jeon; Danica M. Page; Ketan M. Mathavan, PhD; Trevor J. Grant, PhD; Rachel M. Herrup; Cellular Therapies Adoptive immunotherapy; CAR T cells; Solid tumors; T cell; Targeted therapy; Tumor antigens
P151 Solid tumor cytotoxicity by natural killer cells expressing a HER2-directed chimeric antigen receptor enhanced by MyD88/CD40 (MC) Xiaomei Wang, PhD; Daniel E. Jasinski, PhD; Jan L. Medina; David M. Spencer, PhD; Aaron E. Foster, PhD; Joseph H. Bayle, PhD; Cellular Therapies Adoptive immunotherapy; NK/NK T cell; Solid tumors; Targeted therapy
P152 Antigen delivery to PBMCs by microfluidic squeezing primes anti-tumor immunity Matthew G. Booty, PhD; Kelan A. Hlavaty; Emrah I. Ozay, PhD; Carolyne Smith, PhD; Katherine Seidl, PhD; Howard Bernstein, MD, PhD; Armon Sharei; Scott M. Loughhead; Cellular Therapies Adoptive immunotherapy; Antigen presenting cells; T cell; Tumor antigens; Vaccine
P153 Memory CD8+ T cells are more resistant to cancer stem cell (CSC) suppression than effector CD8+ T cells and are more effective at targeting CSC in a murine melanoma model Brooke C. Bredbeck, MD; Shibin Qu; Alicia A. Kevelin; Ashley A. Pepple; amy E. Felsted; Anutosh Ganguly; Clifford S. Cho, MD, FACS; Brooke C. Bredbeck; Cellular Therapies Adoptive immunotherapy; Immune suppression; Stem cell/cancer-initiating cell; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs)
P154 Development of an Antigen-Presenting Bead Kit for Activation and Expansion of Human Antigen-Specific T Cells Yelena Bronevetsky, PhD; Cellular Therapies Adoptive immunotherapy; Antigen presenting cells; CAR T cells; Cytokine; Immune monitoring; T cell; T cell lineages; Tumor antigens
P155 Prospective Translational Study Evaluating Vaccine-Enhanced Adoptive T cell Therapy for Treatment of Osteosarcoma in Companion Dogs Tammie A. Wahaus, BSBA; Noe Reyes, DVM; Jeffrey N. Bryan, DVM, MS, PhD, DACVIM-Oncology; Jeffrey N. Bryan, DVM, MS, PhD, DACVIM-Oncology; Gary W. Wood, PhD; Brian K. Flesner, DVM, MS, DACVIM-Oncology; Debbie Tate, RVT, VTS (Oncology); Lindsay L. Donnelly, DVM, MS, DACVIM-Oncology; Cellular Therapies Adoptive immunotherapy; Neoantigens; Solid tumors; T cell; Tumor antigens; Vaccine
P156 Lung cancer sub-types exhibit differential susceptibility to natural killer cell cytotoxicity Jason G. Cahoon, BS; Shilan Dong, MS; Rafet N. Amoor; Donna L. Sonntag, M.S.; Alexander F. Spurrell; Rachit Ohri, PhD; Cellular Therapies Biomarkers; Chemokine; Cytokine; Immune toxicity; NK/NK T cell; Solid tumors; Targeted therapy; Tumor antigens; Tumor microenvironment
P157 Optimized process for manufacturing Deep-Primed™ T cells creates product with improved functional characteristics and reactivity against multiple tumor-associated antigens Shawn P. Carey, PhD; Christine M. McInnis, PhD; Alicia Worthylake; Angela Forte; Elisabeth Brown; Darren Smith; Kate Sackton, PhD; Rosemary Soucy; Tap Maniar, MD; Karsten Sauer, PhD; Thomas L. Andresen, PhD; Andy Rakestraw, PhD; Cellular Therapies Adoptive immunotherapy; Cytokine; Solid tumors; T cell; T cell lineages; Targeted therapy; Tumor antigens
P158 Suboptimal ER stress Induced Autophagy Regulates Anti-Tumor T Cell Response Shilpak Chatterjee; Danh T. Tran; Kim Dosung; Satish N. Nadig; Carl Atkinson; Hongjun Wang; J. Alan Dieh; Shikhar Mehrotra, PhD; Paramita Chakraborty, PhD; Cellular Therapies Adoptive immunotherapy; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs)
P159 TCR fingerprinting and off-target peptide identification Armen Karapetyan; Chawaree Chaipan; Katharina Winkelbach; Sandra Wimberger; Jun Seop Jeong; Bishnu Joshi; Robert N. Stein, MD PhD; Dennis Underwood, PhD; Eleni Chantzoura, PhD; Alvaro Yague; Jan Bergmann; John C. Castle, PhD; Marc A. Van Dijk, PhD; Marc A. Van Dijk, PhD; Volker Seibert; Cellular Therapies Bioinformatics; Immune toxicity; Neoantigens; T cell
P160 Engineered natural killer cells redirected against adenosinergic immunometabolic suppression for the immunotherapy of lung carcinoma Andrea Chambers, MS; Kyle B. Lupo, BS; Jiao Wang, PhD; Sandro Matosevic, PhD; Cellular Therapies Adoptive immunotherapy; Cytokine; Gene expression; Metabolism; NK/NK T cell; Solid tumors; Targeted therapy; Tumor microenvironment
P161 High-efficiency CAR-T cell manufacturing by improved scalable electroporation Jian Chen, PhD; George Sun; Cellular Therapies Adoptive immunotherapy; CAR T cells; Gene expression; NK/NK T cell; T cell
P162 Development of CD4+ and CD8+ TCRαβ-deficient bioluminescent reporter T cells for screening and characterization of neoantigen-specific TCRs Zhijie J. cheng, PhD; Jamison J. Grailer, PhD; Michael Slater; Pete Stecha; Jim Hartnett; Frank Fan, PhD; Mei Cong, PhD; Cellular Therapies Adoptive immunotherapy; CAR T cells; Neoantigens; T cell; Targeted therapy
P163 Effect of common gamma-chain cytokines on myeloid-derived suppressor cell and M2 macrophage suppressive function: Implications for cellular immunotherapy Anna Cole, BA; Charlotte Rivas; Josue Pineda; Corrine Baumgartner; Stephanie Fetzko; Robin Parihar; Cellular Therapies CAR T cells; Cytokine; Immune suppression; Monocyte/Macrophage; Myeloid cells; MDSC; Solid tumors; Tumor microenvironment
P164 Effect of NK cell treatment on PD-L1 expression and anti-PD-L1 response Alicja Copik, PhD; Jeremiah L. Oyer; Sarah B. Gitto; Deborah A. Altomare, PhD; Cellular Therapies Adoptive immunotherapy; Checkpoint blockade; NK/NK T cell; Solid tumors
P165 Robust, reproducible and highly scalable manufacturing of P-BCMA-ALLO1, an allogeneic CAR-T stem cell memory product for Multiple Myeloma, from numerous healthy donors Stacey Cranert, PhD; Maximilian Richter, PhD; Min Tong, MS; Leslie Weiss, M.S.; Yening Tan, MS; Eric Ostertag, MD/PhD; Julia Coronella, PhD; Devon Shedlock, PhD; Cellular Therapies Adoptive immunotherapy; CAR T cells; T cell; Targeted therapy
P166 ET140202 T-cell therapy for the treatment of liver cancer is built upon a novel antibody-T cell receptor (AbTCR) ARTEMIS™ T-cell platform Jun Cui, PhD; Pengbo Zhang; Hongruo Yun; Yiyang Xu; Lucas Horan, PhD; Shaohua Xu; Sean Xu; Hong Liu; Cellular Therapies CAR T cells; Solid tumors; T cell
P167 Improved efficacy leveraging CAR-T therapeutics that produce tightly controlled, tumor proximal, immunomodulatory outputs Michon Pinnix; Krista McNally; Jay Danao, BS; Melissa Fardy; Rachel Hovde, MS; Charlotte Davis; Nicole Grant; Dianna Lester-Zeiner; David Mai; Ben Wang, PhD; Gus Zeiner, PhD; Cellular Therapies Adoptive immunotherapy; CAR T cells; Cytokine; Gene expression; Immune suppression; Solid tumors; T cell; Tumor microenvironment
P168 Role and Function of T-cell immunoglobulin– and mucin domain–containing (TIM)–3 Receptor on Natural Killer Cells in Solid Tumors Tram N. Dao; Sandro Matosevic, PhD; Cellular Therapies Immune suppression; NK/NK T cell; Solid tumors
P169 Enriching non-genetically modified antigen specific marrow infiltrating lymphocytes (MILs) to target HPV+ oropharyngeal squamous cell carcinoma Danielle W. Dillard, PhD Candidate; Vanessa Chan; LAKSHMI RUDRARAJU, MS; Elizabeth DeOliveira; Amy Thomas; Ervin Griffin; Megan K. Heimann, PhD candidate; Luca Biavati, MD; Elizabeth Zawidzka; Marguerrita El Asmar; Drew M. Pardoll, MD, PhD; Kellie N. Smith, PhD; Carole Fakhry, MD; Ivan M. Borrello, MD; Cellular Therapies Adoptive immunotherapy; Antigen presenting cells; Bioinformatics; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens
P170 Sequential anti-CD19, anti-CD22, and anti-CD20 autologous chimeric antigen receptor T cell (CAR-T) therapies treating a child with relapsed refractory Burkitt lymphoma Juan Du, MD; Yonghong Zhang, Professor; Cellular Therapies B cell; CAR T cells; Leukemia/Lymphoma; Pediatric tumors
P171 T cell receptor gene therapy for a public neoantigen derived from mutated PIK3CA, a dominant driver oncogene in breast and endometrial cancers Smita S. Chandran, PhD; Jiaqi Ma; Martin Klatt, PhD; Friederike Dundar, PhD; Paul Zumbo; Matthew R. Femia; Doron Betel, PhD; David Scheinberg; Brian M. Baker, PhD; Christopher A. Klebanoff, MD; Smita S. Chandran, PhD; Cellular Therapies Adoptive immunotherapy; Gene expression; Neoantigens; Proteomics; T cell
P172 Shape and Material Properties Increase Artificial Antigen Presenting Cell Effectiveness Savannah Est Witte, BS; Kaitlyn G. Calebrisi; Jordan J. Green, PhD; Savannah Est Witte, BS; Cellular Therapies Adoptive immunotherapy; Antigen presenting cells; T cell; Targeted therapy
P173 Case reports: Correlates of response following adoptive transfer of ADP-A2M4, affinity-enhanced T-cells targeting MAGE-A4, in synovial sarcoma Svetlana Fayngerts, PhD; Zohar Wolchinsky; Shravani Shitole; Joana Senra; Rebecca Dryer-Minnerly, PhD; Ruoxi Wang; Jean-Marc Navenot, PhD; Olga Ochkur; Gareth Betts, PhD; Natalie Bath, MSc; Erin Van Winkle; Tom Holdich; Malini Iyengar, PhD; Rafael Amado, MD; Marcus O. Butler, MD; David S. Hong, MD; Alex J. Tipping, PhD; Samik Basu, MD; Indu Ramachandran, PhD Cellular Therapies Adoptive immunotherapy; Clinical study; Cytokine; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment
P174 Combinatorial tumor targeting using a novel switchable RevCAR system Anja Feldmann, PhD; Anja Hoffmann; Ralf Bergmann; Liliana Loureiro, PhD; Enrico Kittel-Boselli; Nicola Mitwasi; Stefanie Koristka; Justyna Jureczek; Nicole Berndt; Claudia Arndt; Michael Bachmann; Cellular Therapies Adoptive immunotherapy; CAR T cells; Targeted therapy
P175 PD-L1: A side-effect of T cell engagement or a main player in MDS tumor immune evasion? Valentina Ferrari, BA; Alison Tarke; Hannah Fields; Tiffany Tanaka; Rafael Bejar; Thomas A. Lane, MD; Antonella Vitiello, PhD; Maurizio Zanetti, MD; Cellular Therapies Adoptive immunotherapy; Myeloid cells; Neoantigens; T cell; Tumor evasion; Tumor microenvironment
P176 Adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) for metastatic uveal melanoma: feasibility of treatment using a product generated from the primary tumor Marie-Andree Forget, PhD; Cara Haymaker, PhD; Orenthial J. Fulbright, BS; Shawne Thorsen, BS; Esteban Flores, BS; Arely Wahl, MSc; Rene J. Tavera, BS; Benjamin Tintera, BS; Timothy L. Woody; Michelle Williams; Yun Shin Chun; Patrick Hwu, MD; Dan S. Gombos; Sapna Patel, MD; Rodabe N. Amaria, MD; Chantale Bernatchez; Cellular Therapies Adoptive immunotherapy; Clinical study; Clinical trial; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs)
P177 NF-kB p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma Rahul Suresh, PhD; David Barakat, PhD; Theresa Barberi, PhD; Lei Zheng, PhD MD; Elizabeth M. Jaffee, MD; Kenneth J. Pienta, MD; Alan D. Friedman, MD; Cellular Therapies Adoptive immunotherapy; Dendritic cell; Monocyte/Macrophage; Myeloid cells; Tumor microenvironment
P178 Dual inhibition of PI3Kdelta and PI3Kgamma to enhance mitochondrial mass and ex vivo expansion of central and stem cell memory T cells from CLL patients Christopher R. Funk, BS; Shuhua Wang, MD; Alexandra Waller, BS; Lauren C. Fleischer, BS; Aditi Sharma; Harold T. Spencer, PhD; Vikas Gupta, MD, PhD; Sruthi Ravindranathan, PhD; Mala Shanmugam, PhD; Christopher Flowers, MD, MS; Edmund K. Waller, MD, PhD, FACP; Cellular Therapies Adoptive immunotherapy; CAR T cells; Costimulation; Leukemia/Lymphoma; T cell
P179 Checkpoint Cbl-b siRNA-based APN401 adoptive cell therapy: Superior efficacy & immune memory induction in murine hepatocellular carcinoma following APN401 monotherapy and synergism with anti-PD1. Anderson Gaweco, MD, PhD; Anderson Gaweco, MD, PhD; Kathrin Thell; Maria Urban; Julia Harrauer; Isabella Haslinger; Josef Penninger; Vincent Chung; Anthony El-Khoueiry, MD; Carlos Becerra, MD; Cellular Therapies Adoptive immunotherapy; Checkpoint blockade; Coinhibition; NK/NK T cell; Solid tumors; T cell; Targeted therapy
P180 SENTI-101, an allogeneic cell product, induces potent and durable anti-tumor immunity in pre-clinical models of peritoneal carcinomatosis Alba Gonzalez Junca, PhD; Gary Lee, PhD; Alba Gonzalez Junca, PhD; Archana Nagaraja, PhD; Alyssa Mullenix; Russell M. Gordley, PhD; Daniel O. Frimannson, PhD; Anissa Benabbas; Chen-Ting Lee, PhD; Tiffany A. Truong; Mengxi Tian; Allison Bi. Quach; Rishi Savur; Rowena Martinez; Alyssa Perry-McNamara; Don-Hong Wang, PhD; Ori Maller, PhD; Dharini Iyer, PhD; Ashita Magal; Christina J. Huynh; Carmina C. Blanco; Jack T. Lin, PhD; Brian S. Garrison, PhD; Philip Lee, PhD; Sravani Mangalampalli; Timothy K. Lu, MD, PhD; Cellular Therapies Adoptive immunotherapy; Cytokine; Solid tumors; Tumor microenvironment
P181 Multi-phenotype CRISPR-Cas9 screens identify p38 kinase as a target for adoptive immunotherapies Devikala Gurusamy, PhD; Suman Vodnala; Amanda Henning; Rigel Kishton; Tori N. Yamamoto; Arash Eidizadeh; Li Jia; Christine M. Kariya; Mary Black; Robert L. Eil; Douglas Palmer; Zhiya Yu; Jenny Pan, MD; Madhusudhanan Sukumar; Shashank J. Patel; Nicholas P. Restifo, MD; Cellular Therapies Adoptive immunotherapy; Bioinformatics; CAR T cells; Leukemia/Lymphoma; Metabolism; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor antigens
P182 GAIA-102: a new class NK cell-like phenotype manufactured in accordance with GMP/GCTP that can eliminate solid tumors Yui Harada, PhD; Yoshikazu Yonemitsu, MD, PhD; Cellular Therapies Adoptive immunotherapy; MDSC; NK/NK T cell; Solid tumors
P183 Development of novel chimeric antigen receptor T cells for immunotherapy of hepatocellular carcinoma Yukai He, PhD; Leidy Caraballo Galva; Xiaotao Jiang; Cellular Therapies Adoptive immunotherapy; Antibody
P184 Activating marrow infiltrating lymphocytes in hypoxia enhances their efficacy in adoptive T-cell therapy Megan K. Heimann, PhD candidate; Ervin Griffin; Luca Biavati, MD; Amy Thomas; Danielle Dillard; Elizabeth Zawidzka; Brianna Richardson; Robert D. Leone; Gregory Szeto; Kimberly A. Noonan, PhD; Ivan M. Borrello, MD; Cellular Therapies Adoptive immunotherapy; Cytokine; Gene expression; Metabolism; T cell; Tumor antigens; Tumor microenvironment
P185 T cell antigen presenting cell (tAPC) is a strategy to induce CAR T expansion in vivo in the absence of a tumor for on-target toxicity studies Yen Ho, BS; Jon Jones, BA; Jon Jones, BA; Patrick Carlson, BS; Patrick Carlson, BS; Cyr de Imus; Rebekah Turk; Dina Alcorn; Kyle Kolaja; Ruth Salmon, PhD; Thomas Long; Cellular Therapies Adoptive immunotherapy; Antigen presenting cells; CAR T cells; Immune toxicity; T cell
P186 Evaluation of antigen-specific T-cell immunity at the single cell level using large panels of DNA barcoded MHC multimers Kivin KJ. Jacobsen, PhD; Dagmar Walter; Michael Stubbington; Katherine Pfeiffer; Charlotte Halgreen; Liselotte Brix, phd; Stephane Boutet; Kivin KJ. Jacobsen, PhD; Cellular Therapies Adoptive immunotherapy; Biomarkers; Gene expression; Immune monitoring; Neoantigens; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens
P187 Single-cell RNA sequencing and functional assessment of healthy donor- and cancer patient-derived T and CAR-T cells Zinkal Padalia, MS; Konstantinos Karagiannis, PhD; Brigid Mcewan, MA; Vahan Simonyan, PhD; Jonathan Terrett, PhD; Demetrios Kalaitzidis, PhD; Demetrios Kalaitzidis, PhD; Cellular Therapies Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; Systems biology; T cell; Targeted therapy; Tumor antigens
P188 Enhanced anti-tumor activity of human placental CD34+ derived natural killer cells in combination with ACY-241 for multiple myeloma immunotherapy Lin Kang, PhD; Xiaokui Zhang; Shuyang He; Vanessa Voskinarian-Berse; Bhavani Stout; Valentina Rousseva; William van der Touw; James Edinger; Robert Hariri; Cellular Therapies Adoptive immunotherapy; Chemotherapy; NK/NK T cell
P189 Tumor Treating Fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy Noa Kaynan, PhD; Tali Voloshin; Shiri Davidi; Yaara Porat; Anna Shteingauz; Mijal Munster; Rosa S. Schnaiderman; Catherine Tempel Brami; Yaniv Alon; Einav Zeevi; Karnit Gotlib; Roni Blat; Orni Tal Yitzhaki; Shay Cahal; Aviran Itzhaki; Eilon D. Kirson; Uri Weinberg, MD PhD; Adrian Kinzel; Yoram Palti; Noa Kaynan, PhD; Moshe Giladi; Cellular Therapies Checkpoint blockade; Dendritic cell; Immune adjuvant; Solid tumors
P190 Single-day CAR manufacturing platform using mRNA and Flow Electroporation Technology Michael Kuo; Robert Keefe, PhD; Linhong Li, PhD; Angelia Viley; Mary Loveras; Brian Mulhern; Melanie Hartsough; Robert Keefe, PhD; Claudio A. Dansky Ullmann, MD; Dhana Chinnasamy; Cellular Therapies CAR T cells; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy
P192 Anti-HLA-G Antigen Receptor T-Cells Exhibit Potent Anti-Tumor Effects Against Human Solid Tumors Alan L. Epstein, MD, PhD; Aida Kouhi, PhD candidate; Cellular Therapies CAR T cells; Neoantigens; Solid tumors; T cell; Targeted therapy; Tumor antigens
P193 CoStAR (Costimulatory Antigen Receptor) Enhancement of Tumour Infiltrating Lymphocyte Therapy Gray Kueberuwa, PhD; John S. Bridgeman, PhD; Martina Sykorova; milena Kalaitsidou; Michelle L. Le Brocq; Martina Sykorova; Robert Hawkins; Cellular Therapies Adoptive immunotherapy; Costimulation; Immune contexture; T cell; Tumor infiltrating lymphocytes (TILs)
P194 Use of stimulatory cells in conjunction with IL-12 and IL-18 augments NK cell expansion and transduction, drives a memory phenotype, and improves in vitro and in vivo CAR NK activity Anmol Vohra, MS; Katherine Jamboretz, MS; Sasha Lazetic; Denise Gonzalez; Daofeng Liu, PhD; Ivan Chan, PhD; James B. Trager, PhD; Cellular Therapies Cytokine; NK/NK T cell
P195 Loss of function of the TSC1-TSC2 complex renders tumors eligible for GD3 CART therapy Ancy Thomas; Saurav Sumughan; Zhussipbek Mukhatayev; Emilia Dellacecca; Nicola Lancki; Levi Barse; Jesus Zamora-Pineda; Suhail Akhtar; Maria Picken; Denise Scholtens; Daniel Dilling; Richard P. Junghans, PhD, MD; Caroline Le Poole; Cellular Therapies Adoptive immunotherapy; CAR T cells; NK/NK T cell; Solid tumors; T cell; Tumor antigens
P196 The first step toward the universal cell therapy: Simultaneous removal of HLAs (Human leukocyte antigens) using CRISPR-mediated quadruple genome editing in allogeneic T cells Jeewon Lee, Ph D; Munkyung Kim; Joong Hyuk Sheen; Jihye Ryu; Yu Young Kim; Okjae Lim; Cellular Therapies Adoptive immunotherapy; Gene expression; T cell
P197 The development of an autologous neoantigen specific T cell product from peripheral blood, NEO-PTC-01, through the ex-vivo induction protocol, NEO-STIM™ Divya R. Lenkala; Marit M. Van Buuren, PhD; Brian McCarthy; Jessica Kohler, PhD; Michael Nelson; Flavian Brown; Yvonne Ware, Masters; Yuting Huang, Master of Science; Janani Sridar; Yusuf S. Nasrullah, Master's in Biological Research, United Kingdom; Dewi Harjanto; Joost H. Van Den Berg, PharmD; Matthew Goldstein, MD, PhD; Richard B. Gaynor, MD; Cellular Therapies Adoptive immunotherapy; Antigen presenting cells; Bioinformatics; Immune monitoring; Neoantigens; T cell
P198 Short-lived and extended half-life target modules for redirecting UniCAR T-cells against sialyl-Tn expressing cancer cells Liliana Loureiro, PhD; Liliana Loureiro, PhD; Anja Feldmann, PhD; Ralf Bergmann; Stefanie Koristka; Nicole Berndt; Nikolett Hegedüs; Domokos Máthé; Paula Videira; Michael Bachmann; Claudia Arndt; Cellular Therapies Adoptive immunotherapy; CAR T cells; Solid tumors; Targeted therapy
P199 Generation of functionally and phenotypically mature, allogeneic natural killer cells from human induced pluripotent stem cells under chemically-defined, feeder- and serum- free culture conditions Kyle B. Lupo, BS; Andrea Chambers, MS; Sandro Matosevic, PhD; Cellular Therapies Adoptive immunotherapy; NK/NK T cell; Stem cell/cancer-initiating cell; Solid tumors
P200 CART-engineered Marrow-infiltrating Lymphocytes (MILsTM) are more polyfunctional than their matched peripheral blood counterparts Eric R. Lutz, PhD; LAKSHMI RUDRARAJU, MS; Elizabeth DeOliveira; Srikanta Jana; Jing Zhou, MD, PhD; Sean G. Mackay, MBA; Ivan M. Borrello, MD; Kimberly A. Noonan, PhD; Eric R. Lutz, PhD; Cellular Therapies Adoptive immunotherapy; CAR T cells; T cell
P201 Comparison of phenotype and anti-tumor profile of CD19-CAR-T cells generated from either umbilical cord blood- or peripheral blood-derived T lymphocytes Cristina Maccalli, PhD; Dhanya Kizhakayil, PhD; Shilpa Ravindran, BSc.; Saad Rasool; Rebecca Mathew; Valentina Mattei; Monica Casucci, PhD; Sara Deola, MD, PhD; Chiara Cugno, MD; Damien Chaussabel; Sara Tomei, PhD; Christof von Kalle; Cristina Maccalli, PhD; Cellular Therapies Adoptive immunotherapy; CAR T cells; Cytokine; Gene expression; Immune monitoring; Leukemia/Lymphoma; Systems biology; T cell; Tumor antigens
P202 Mechanisms underlying human placental CD34+-derived natural killer cell cytotoxicity against glioblastoma Tanel Mahlakoiv, PhD; Bhavani Stout; Valentina Rousseva; Irene Raitman; Lin Kang, PhD; Robert Hariri; Xiaokui Zhang; William van der Touw; Tanel Mahlakõiv; Cellular Therapies Adoptive immunotherapy; Gene expression; NK/NK T cell; Solid tumors
P203 Discovery and characterization of the first fully human Phosphopeptide Tumor Target-specific T cell receptor Xavier Michelet, PhD; Eleni Chantzoura, PhD; Ekaterina Breous-Nystrom, PhD; Alessandra Franchino; Rachel Smith; Daniel Pollacksmith; Jan Bergmann; Alvaro Sebastian Yague; Paisley T. Myers, PhD; Erin Jeffrey; Benjamin Wolf; Dennis Underwood, PhD; Marc A. Van Dijk, PhD; Arthur A. Hurwitz, PhD; Cellular Therapies Adoptive immunotherapy; Leukemia/Lymphoma; Neoantigens; T cell; Targeted therapy; Tumor antigens
P204 Ex vivo-activated allogeneic CD4+ T-cells disrupt immunosuppressive tumor microenvironment, and induce host tumor-specific cytotoxic T-cells in mice Kazuhiro Mochizuki, MD, PhD; Shogo Kobayashi; Nobuhisa Takahashi; Hideki Sano; Yoshihiro Ohara; Shin Mineishi, MD; Yi Zhang; Atsushi Kikuta; Cellular Therapies Adoptive immunotherapy; Antigen presenting cells; Dendritic cell; Inflammation; Monocyte/Macrophage; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P205 Automated, Closed Bioreactors for T Cell Processing and Dendritic Cell-T Cell Co-Culture Lekhana Bhandary, BS, PhD; Andrew Kozbial, BS, PhD; Shashi Murthy, BS, PhD; Shashi Murthy, BS, PhD; Cellular Therapies CAR T cells; Dendritic cell; Monocyte/Macrophage; Neoantigens; T cell
P206 Transmembrane and linker domain amino acid composition alters chimeric antigen receptor (CAR) membrane residence and may conceal detection of novel functional CAR formats Dina Schneider, PhD; Virginia Hoglund, MS; Ying Xiong, PhD; Darong Wu, MS; Boro Dropulic, PhD, MBA; Rimas J. Orentas, PhD; Rimas J. Orentas, PhD; Rimas J. Orentas, PhD; Cellular Therapies Adoptive immunotherapy; CAR T cells; T cell
P207 A patient-driven ex vivo 3D tumor organoid model to assess efficacy of tumor infiltrating T-cell adoptive cell therapy Jenny Kreahling, PhD; Mibel Pabon, PhD; Mibel Pabon, PhD; Melba Page, PhD; Vijayendra Agrawal, PhD; Soner Altiok, MD, PhD; Cellular Therapies Adoptive immunotherapy; Biomarkers; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
P208 Impact of combined blockade of PD1 and activation of CD137 on tumor infiltration and tumor cell killing efficacy of TILs in an ex vivo autologous 3D tumoroid model of NSCLC patient samples. Jenny Kreahling, PhD; Melba Page, PhD; Melba Page, PhD; Mibel Pabon, PhD; Vijayendra Agrawal, PhD; Soner Altiok, MD, PhD; Cellular Therapies Adoptive immunotherapy; Antibody; Checkpoint blockade; Cytokine; Immune monitoring; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P209 Hijacking CAR-CD19 T cells to potently control Her2-positive solid tumors in vitro and in vivo through the use of unique and selective bridging proteins Paul Rennert, PhD; Christine Ambrose, PhD; Fay Dufort, PhD; Lihe Dufort; Alyssa Birt; Thomas Sanford; Lan Wu; Roy Lobb, PhD; Cellular Therapies Adoptive immunotherapy; CAR T cells; Solid tumors; Tumor antigens; Tumor evasion
P210 Deep phenotypic and functional analysis of transduced anti-CD19 CAR T cells and untransduced T cells in patients treated with axi-cel by single cell mass cytometry Yohei Arihara, MD, PhD; Caron Jacobson, MD; Philippe Armand, MD; John M. Rossi, MS; Nathalie Scholler, MD, PhD; Stuart Sievers, PhD; Edmund Chang, PhD; Mauro Avanzi, MD, PhD; Adrian Bot, MD, PhD; Jerome Ritz, MD; Cellular Therapies Adoptive immunotherapy; CAR T cells; Clinical study; Immune monitoring; Leukemia/Lymphoma
P211 Combining Deep™ IL-12 Primed and Deep™ IL-15 Primed T cells leverages complementary mechanisms to enhance anti-tumor activity Katharine Sackton, PhD; Elena Geretti, PhD; Pengpeng Cao, PhD; Shawn P. Carey, PhD; Xiaoyan Liang; Jonathan Nardozzi, PhD; Zishu Gui; Alicia Worthylake; Glenn Leary; Becker Hewes, MD; Tap Maniar, MD; Jonathan B. Fitzgerald, PhD; Andy Rakestraw, PhD; Karsten Sauer, PhD; Douglas Jones, PhD; Thomas L. Andresen, PhD; Cellular Therapies Adoptive immunotherapy; Cytokine; Solid tumors; T cell
P212 Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy Donastas Sakellariou-Thompson, BS; Marie-Andree Forget, PhD; Emily Hinchcliff, MD; Joseph Celestino; Patrick Hwu, MD; Amir A. Jazaeri, MD; Cara Haymaker, PhD; Chantale Bernatchez; Cellular Therapies Adoptive immunotherapy; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs)
P213 Conversion of peripheral blood mononuclear cells into tumor-specific cytolytic cell populations using tumor cells engineered with multiple immunomodulatory factors Joshua Keegan; James Lederer; Frank Borriello, MD, PhD; Nathan Schomer, MS; James Lederer; Cellular Therapies Adoptive immunotherapy; Antigen presenting cells; Costimulation; Cytokine; Immune adjuvant; NK/NK T cell; T cell; T cell lineages; Targeted therapy; Vaccine
P214 T cells precision engineered to express neoepitope-specific TCRs cloned from a patient with colorectal cancer specifically target and kill relevant neoantigen-expressing tumor cells Barbara Sennino, PhD; Adam Litterman; John Gagnon; Andrew Conroy; Bhamini Purandare; Zheng Pan, PhD; Dalmas Olivier; Kyle Jacoby, PhD; Songming Peng, PhD; Alex Franzusoff, PhD; Stefanie J. Mandl, PhD; Cellular Therapies Adoptive immunotherapy; Neoantigens
P215 Depletion of CD45RA-positive cells potentiates the reactivation of EBV-specific T-cells from EBV positive lymphoma patients Sandhya Sharma, BSc.; Sandhya Sharma, BSc.; Naren Mehta; Kathan Parikh, RA; Cliona M. Rooney, PhD; Cellular Therapies Adoptive immunotherapy; Antigen presenting cells; T cell; Tumor antigens
P217 An NK cell line (PD-L1 t-haNK) engineered to target PD-L1 efficiently kills tumor cells and myeloid derived suppressor cells Kellsye Fabian, PhD; Michelle Padget; Renee N. Donahue, PhD; kristen solocinski, PhD; Clint T. Allen, MD; John Lee, MD; Patrick Soon-Shiong, MD; Jeffrey Schlom, PhD; James W. Hodge, PhD, MBA; Cellular Therapies MDSC; NK/NK T cell; Solid tumors; Targeted therapy
P218 A novel, bioluminescent assay for the selective detection of target cell killing in mixed cultures Richard Somberg, PhD; Brock Binkowski; Aileen Paguio; Peter Stecha; Chris Eggers; Braeden Butler; Michael Beck; Julia Gilden, PhD; Jey Cheng; Mei Cong, PhD; Frank Fan, PhD; Cellular Therapies Adoptive immunotherapy; Antibody; CAR T cells; Chemokine; Costimulation; Cytokine; NK/NK T cell; T cell; Targeted therapy
P220 Targeting neoantigens with immunotherapy: Are we limited to pre-existing autologous neoantigen-specific T-cells? Aline Bracher; Slavoljub Milosevic; Daniel Sommermeyer; Daniel Sommermeyer; Cellular Therapies Adoptive immunotherapy; Neoantigens; Tumor antigens
P221 Superior anti-tumor activity of metabolically enhanced bispecific antibody armed CAR-less Bionic T cells Archana Thakur, PhD; John Scholler; Edwin T. Bliemeister; Carl H. June, MD; Lawrence G. Lum, MD, DSc; Cellular Therapies Adoptive immunotherapy; Antibody; Chemokine; Cytokine; Solid tumors; T cell; Targeted therapy
P222 Modulating BRD4 in T cells using self-delivery RNAi to improve adoptive cell therapy of cancer Jeroen Melief, PhD; Laura L. Van Leeuwe Kirsch, BSc; Esmeralda Hemme; John A. Barrett, PhD; Simon P. Fricker, PhD; Gerrit Dispersyn, PhD; Rolf Kiessling, MD, PhD; Cellular Therapies Adoptive immunotherapy; CAR T cells; T cell; Tumor infiltrating lymphocytes (TILs)
P224 Case studies of sarcoma and MRCLS following treatment with NY-ESO-1 TCR T Cells (GSK3377794): correlates of predictable response characteristics Brian Van Tine, MD, PhD; Sandra P. D'Angelo, MD; Alexandra Gyurdieva; Laura Johnson; David C. Turner; Jenna Tress; M. Phillip DeYoung; Yuehui Wu; Aisha N. Hasan, MBBS MD; Dejka Araujo, MD; Cellular Therapies Adoptive immunotherapy; Clinical study; Cytokine; T cell
P225 Generating iPSC-derived CAR T cells with an endogenous T cell phenotype and conventional CAR T functionality Zhiqiang (Daniel) Wang, Ph.D; Zhiqiang (Daniel) Wang, Ph.D; Hellen McWilliams-Koeppen, MS; Christian Huynh, BS; Hernan Reza; Vibhuti Vyas; Xiuli Wang, PhD; Wen-Chung Chang, MS; Julie R. Ostberg, PhD; Renate Starr, MS; Jamie Wagner; Brenda Aguilar, BS; Xiwei Wu; Jinhui Wang; Wei Chen; Chris Seet; Gay Crooks; Christine Brown, PhD; Stephen J. Forman, MD; Cellular Therapies Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; Stem cell/cancer-initiating cell; T cell; T cell lineages
P226 Iovance Gen2 TIL manufacturing process produces drug products that exhibit favorable quality attributes for adoptive cell transfer across 5 solid tumor indications Seth Wardell; Seth Wardell; Maritza Lienlaf-Moreno; Lavakumar Karyampudi; Anand Veerapathran, PhD; Ian Frank; Michelle A. Blaskovich, BS; Kenneth Onimus; Arvind Natarajan; Maria Fardis, PhD, MBA; Joe Wypych Cellular Therapies Adoptive immunotherapy; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs)
P227 Co-expression of the metabolic enzyme GOT2 with a GPC3-targeted CAR-T overcomes challenges of the solid tumor microenvironment, substantially improving therapeutic efficacy in solid tumor xenografts Kathleen R. Whiteman, MS; Kathleen R. Whiteman, MS; Tapasya Pai; Eugene Choi; Taylor Hickman; Tyler Johnson; Luke Barron, PhD; Taylor Friedman; Madaline Gilbert; Binzhang Shen; Seth Ettenberg; Kathleen McGinness; Greg Motz; Cellular Therapies Adoptive immunotherapy; CAR T cells; Metabolism; Solid tumors; T cell; Tumor microenvironment
P228 Tumor infiltrating lymphocyte recognition of shared neoantigens from mutated DNA repair/remodeling proteins in a patient with metastatic pancreatic adenocarcinoma Ghanshyam Singh S. Yadav, PhD; Chetana Bhaskarla, PhD; Smriti Chaurasia, PhD; Joshua Tobin; Xinming Zhuo; Yinghong Pan; Annerose Berndt; Udai S. Kammula, MD, FACS; Cellular Therapies Adoptive immunotherapy; Neoantigens; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs)
P229 The Next Generation “off-the-shelf” Universal CAR for Adoptive Immunotherapy Weichih Yang, PhD; Yun Ji; Xiaobing Luo; Huijuan Cui; Michael Patrick; Yutian Wei; Shigui Zhu; Jiaqi Huang; Xin Yao; Yihong Yao; Aibing Liang; Ping Li; Cellular Therapies Adoptive immunotherapy; CAR T cells; T cell; T cell lineages
P230 Activating Antigen Carriers for Cancer Therapy: Preclinical Immune Responses Drive Tumor Regression Defne Yarar, PhD; Amritha Ramakrishnan; Katarina Blagovic, PhD; Katherine Seidl; Howard Bernstein, MD, PhD; Armon Sharei; Cellular Therapies Adoptive immunotherapy; Immune adjuvant; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine
P231 Invariant natural killer T cells as an allogeneic cell therapy platform Burcu Yigit, PhD; Xavier Michelet, PhD; Simon Yue; Darrian Moskowitz; Mark Exley; Burcu Yigit, PhD; Cellular Therapies Adoptive immunotherapy; NK/NK T cell
P232 Characterization of ADCC Resistance in Multiple Cancer Types David Zahavi, MS, BS; Yongwei ZHANG; Sandra Jablonski, PhD; Louis M. Weiner, MD; Cellular Therapies Antibody; NK/NK T cell; Targeted therapy; Tumor antigens; Tumor evasion
P233 RTX-321, an Allogeneic Artificial Antigen Presenting Red Cell Therapeutic, Expressing MHC I-Peptide, 41BBL and IL12, Promotes Antigen-Specific T Cell Expansion and Anti-Tumor Activity in HPV16+ Tumors Xuqing Zhang, PhD; Tiffany F. Chen; Cellular Therapies Antigen presenting cells; Costimulation; Cytokine; T cell; Tumor antigens
P234 DAP10 and DAP12 Signaling Based CAR Circumvents Ligand-dependent Tonic Signaling and Mediates Potent Anti-tumor Response In Vivo Alan L. Epstein, MD, PhD; Long Zheng, PhD Candidate; Cellular Therapies CAR T cells; Immune toxicity; Neoantigens; T cell; Targeted therapy; Tumor antigens